Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer

Matthew E. Nielsen, Mark L Gonzalgo, Mark P. Schoenberg, Robert H. Getzenberg

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Among genitourinary malignancies, bladder cancer is a common, potentially dangerous and exceedingly costly disease entity. Predicated on substantial gains in our understanding of the natural history and molecular biology of bladder cancer, recent years have seen an explosion of new applied technologies to aid clinicians in the management of bladder cancer. Herein we present a systematic overview of general conceptual issues and specific strategies of potential relevance to the clinical evaluation of patients with bladder cancer. A number of basic epidemiological issues provide the relevant background within which we should consider candidate biomarkers. Within this framework, we highlight a number of important recent research findings representative of the large number of candidate bladder cancer biomarkers that have emerged. With several markers already having obtained regulatory approval for clinical use, this topic is of clear relevance not only to researchers but also to the practicing physician. Bladder cancer is a common, costly, and potentially dangerous disease with the opportunity for significant technological inroads in the area of applied biomarkers. An appreciation of basic epidemiological considerations informs our consideration of the state of the art and identifies specific strategies amenable to further innovation.

Original languageEnglish (US)
Pages (from-to)499-508
Number of pages10
JournalWorld Journal of Urology
Volume24
Issue number5
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Explosions
Tumor Biomarkers
Natural History
Molecular Biology
Research Personnel
Technology
Physicians
Research
Neoplasms

Keywords

  • Bladder cancer
  • Detection
  • Markers
  • Surveillance
  • Urine

ASJC Scopus subject areas

  • Urology

Cite this

Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. / Nielsen, Matthew E.; Gonzalgo, Mark L; Schoenberg, Mark P.; Getzenberg, Robert H.

In: World Journal of Urology, Vol. 24, No. 5, 11.2006, p. 499-508.

Research output: Contribution to journalArticle

Nielsen, Matthew E. ; Gonzalgo, Mark L ; Schoenberg, Mark P. ; Getzenberg, Robert H. / Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. In: World Journal of Urology. 2006 ; Vol. 24, No. 5. pp. 499-508.
@article{f173c6563a5c4d51875004e2fa025cc5,
title = "Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer",
abstract = "Among genitourinary malignancies, bladder cancer is a common, potentially dangerous and exceedingly costly disease entity. Predicated on substantial gains in our understanding of the natural history and molecular biology of bladder cancer, recent years have seen an explosion of new applied technologies to aid clinicians in the management of bladder cancer. Herein we present a systematic overview of general conceptual issues and specific strategies of potential relevance to the clinical evaluation of patients with bladder cancer. A number of basic epidemiological issues provide the relevant background within which we should consider candidate biomarkers. Within this framework, we highlight a number of important recent research findings representative of the large number of candidate bladder cancer biomarkers that have emerged. With several markers already having obtained regulatory approval for clinical use, this topic is of clear relevance not only to researchers but also to the practicing physician. Bladder cancer is a common, costly, and potentially dangerous disease with the opportunity for significant technological inroads in the area of applied biomarkers. An appreciation of basic epidemiological considerations informs our consideration of the state of the art and identifies specific strategies amenable to further innovation.",
keywords = "Bladder cancer, Detection, Markers, Surveillance, Urine",
author = "Nielsen, {Matthew E.} and Gonzalgo, {Mark L} and Schoenberg, {Mark P.} and Getzenberg, {Robert H.}",
year = "2006",
month = "11",
doi = "10.1007/s00345-006-0116-9",
language = "English (US)",
volume = "24",
pages = "499--508",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer

AU - Nielsen, Matthew E.

AU - Gonzalgo, Mark L

AU - Schoenberg, Mark P.

AU - Getzenberg, Robert H.

PY - 2006/11

Y1 - 2006/11

N2 - Among genitourinary malignancies, bladder cancer is a common, potentially dangerous and exceedingly costly disease entity. Predicated on substantial gains in our understanding of the natural history and molecular biology of bladder cancer, recent years have seen an explosion of new applied technologies to aid clinicians in the management of bladder cancer. Herein we present a systematic overview of general conceptual issues and specific strategies of potential relevance to the clinical evaluation of patients with bladder cancer. A number of basic epidemiological issues provide the relevant background within which we should consider candidate biomarkers. Within this framework, we highlight a number of important recent research findings representative of the large number of candidate bladder cancer biomarkers that have emerged. With several markers already having obtained regulatory approval for clinical use, this topic is of clear relevance not only to researchers but also to the practicing physician. Bladder cancer is a common, costly, and potentially dangerous disease with the opportunity for significant technological inroads in the area of applied biomarkers. An appreciation of basic epidemiological considerations informs our consideration of the state of the art and identifies specific strategies amenable to further innovation.

AB - Among genitourinary malignancies, bladder cancer is a common, potentially dangerous and exceedingly costly disease entity. Predicated on substantial gains in our understanding of the natural history and molecular biology of bladder cancer, recent years have seen an explosion of new applied technologies to aid clinicians in the management of bladder cancer. Herein we present a systematic overview of general conceptual issues and specific strategies of potential relevance to the clinical evaluation of patients with bladder cancer. A number of basic epidemiological issues provide the relevant background within which we should consider candidate biomarkers. Within this framework, we highlight a number of important recent research findings representative of the large number of candidate bladder cancer biomarkers that have emerged. With several markers already having obtained regulatory approval for clinical use, this topic is of clear relevance not only to researchers but also to the practicing physician. Bladder cancer is a common, costly, and potentially dangerous disease with the opportunity for significant technological inroads in the area of applied biomarkers. An appreciation of basic epidemiological considerations informs our consideration of the state of the art and identifies specific strategies amenable to further innovation.

KW - Bladder cancer

KW - Detection

KW - Markers

KW - Surveillance

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=33751242321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751242321&partnerID=8YFLogxK

U2 - 10.1007/s00345-006-0116-9

DO - 10.1007/s00345-006-0116-9

M3 - Article

C2 - 17102951

AN - SCOPUS:33751242321

VL - 24

SP - 499

EP - 508

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 5

ER -